Scarica l'app Stockscreener
44.38
1.84%
0.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$43.58
Aprire:
$44.07
Volume 24 ore:
1.10M
Relative Volume:
1.72
Capitalizzazione di mercato:
$2.58B
Reddito:
$776.83M
Utile/perdita netta:
$-29.02M
Rapporto P/E:
-86.68
EPS:
-0.512
Flusso di cassa netto:
$82.25M
1 W Prestazione:
-2.57%
1M Prestazione:
-8.17%
6M Prestazione:
-9.94%
1 anno Prestazione:
+34.65%
Intervallo 1D:
$43.54
$44.58
Intervallo di 1 settimana:
$42.45
$45.71
Portata 52W:
$30.83
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
44.38 | 2.58B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Supernus Pharmaceuticals shareholders approve director elections and key proposals - Investing.com UK
Supernus Pharmaceuticals shareholders approve director elections and key proposals By Investing.com - Investing.com Nigeria
Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan - Stock Titan
Behavioral Patterns of SUPN and Institutional Flows - Stock Traders Daily
Supernus Pharmaceuticals Inc (SUPN) Institutional Confidence - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Inc (SUPN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record - Investing.com
Supernus Pharmaceuticals Inc - TradingKey
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record - GlobeNewswire
Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sage Therapeutics Inc Stock (US78433J1043): Quiet trading as investors await next catalysts after Su - AD HOC NEWS
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead - Yahoo! Finance Canada
(SUPN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
SUPN Stock Price, Quote & Chart - ChartMill
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - MSN
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year - AOL.com
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
Why Supernus Pharmaceuticals Shares Surged - AOL.com
Supernus Pharmaceuticals to present at June healthcare investor conferences - Pluang
Drugmaker Supernus heads to New York and Miami for June investor events - Stock Titan
Supernus Pharmaceuticals to Participate in June Investor Conferences - GlobeNewswire
How (SUPN) Movements Inform Risk Allocation Models - Stock Traders Daily
SUPN PE Ratio & Valuation, Is SUPN Overvalued - Intellectia AI
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 2026 Earnings: Robust EPS Beat Overshadowed by Mild Share DeclinePeak Earnings Alert - lwvtexas.org
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment By Investing.com - Investing.com Australia
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Supernus Reaches Milestone, Triggers Contingent Value Rights Payment - TipRanks
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone. - Bitget
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Three Growth Stocks Under Pressure: Supernus, RGA, and Black Stone MineralsNews and Statistics - IndexBox
Supernus Pharmaceuticals Q1 2026 Financial Results and Analyst Call HighlightsNews and Statistics - IndexBox
Trading Systems Reacting to (SUPN) Volatility - Stock Traders Daily
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
TradingKey - TradingKey
Supernus Pharmaceuticals reports strong demand rebound after resolving supply constraints in March 2026 - Pluang
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed? - Sahm
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
Supernus (SUPN) Q1 2026 Earnings Transcript - AOL.com
Supernus Pharmaceuticals Q1 Loss Narrows To US$0.04 EPS Challenging Persistent Bearish Narrative - Sahm
SUPN Technical Analysis & Stock Price Forecast - Intellectia AI
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance - Sahm
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - The Globe and Mail
Supernus Pharmaceuticals Reports Strong Q1 2026 Results with 56% Revenue Growth - IndexBox
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference - The Manila Times
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.23%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):